A postgraduate researcher at NUI Galway has been awarded a fellowship at a prestigious University in Germany to advance his work in the field of cardiac tissue engineering. Michael Monaghan was awarded the fellowship by the European Molecular Biology Organisation (EMBO) and will allow Michael to further his research in Germany until January 2012.  

Michael Monaghan, originally a graduate of NUI Galway’s Degree in Biomedical Engineering, will spend three months working with the Franhofer IGB Institute and University Tübingen in Stuttgart, which have a long history of cardiovascular and tissue engineering research. 

Describing the opportunity Michael, from Mohill, Co Leitrim, says: “This fellowship will allow me a unique opportunity to test our functional biomaterial in one of the best research labs in Europe. These three months should prove invaluable to my research career and create collaborative links with some of the best scientists in Europe.”

Michael is in the final year of his PhD programme under the supervision of Professor Abhay Pandit, Director of the Network of Excellence for Functional Biomaterials (NFB), an SFI-funded Strategic Research Cluster at NUI Galway. His research on the delivery interfering RNA (RNAi), an emerging field of non-viral gene therapy, is leading to a clearer understanding of RNAi’s therapeutic potential. Specifically, Michael is investigating the modulation of scarring of the myocardium following myocardial infarction (MI) aiming to aid the body to heal itself by silencing detrimental cell processes. 

Cardiovascular disease is the most significant cause of morbidity in the developed world and there is currently no technique for regeneration of infarcted myocardium. One of the NFB’s goals is to develop scaffold-based cardiac gene therapy to minimize damage, promote regeneration and modulate the fibrotic response in cardiac tissues following MI. The research conducted by Michael would ultimately be of benefit to patients at risk of heart failure following MI, leading to a decrease in morbidity and improved heart function. 

According to Professor Pandit: “NUI Galway has established a critical mass in the area of developing the next-generation biomaterials in Ireland. Each individual researcher is playing an important part in our work and Michael is a perfect example.  His research is advancing the field of tissue engineering and will have possible applications in cardiac and skin regeneration following injury.” 

 -ends-